Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up days 14 and 28
Summary
This trial is testing two new medications, K-757 and K-833, in overweight or obese patients with Type 2 diabetes. The goal is to see if these medications are safe, how they move through the body, and what effects they have.
Eligible Conditions
- Diabetes
- Obesity
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ days 14 and 28
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~days 14 and 28
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Proportion of participants who discontinued study medication due to an AE
Proportion of participants who experienced 1 or more treatment-emergent AEs
Secondary study objectives
AUC of plasma K-833
Area under the concentration-time curve [AUC] of plasma K-757
Cl of plasma K-833
+9 moreTrial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: K-757 and K-833 combinationExperimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
K-757 and K-833
2023
Completed Phase 2
~240
Find a Location
Who is running the clinical trial?
Kallyope Inc.Lead Sponsor
3 Previous Clinical Trials
235 Total Patients Enrolled
3 Trials studying Obesity
235 Patients Enrolled for Obesity
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Share this study with friends
Copy Link
Messenger